Investigation of metformin (MET) in patients with castration resistant prostate cancer (CRPC) in combination with enzalutamide (ENZ) vs. ENZ alone: A randomized, open label, phase 2 trial. SAKK 08/14—IMPROVE.

• Rothermundt, Christian Alexander Kantonsspital St Gallen, St Gallen, Switzerland;
• Cathomas, Richard Kantonsspital Graubuenden, Chur, Switzerland;
• Xyrafas, Alexandros SAKK - Swiss Group for Clinical Cancer Research, Coordinating Center, Bern, Switzerland;
• Schneider, Martina SAKK - Swiss Group for Clinical Cancer Research, Coordinating Center, Bern, Switzerland;
• Biaggi Rudolf, Christine Swiss Group for Clinical Cancer Research, Bern, Switzerland;
• Roggero, Enrico Medical Oncology/Hematology, Bellinzona, Switzerland;
• Fischer, Natalie Kantonsspital Winterthur, Winterthur, Switzerland;
• Rothschild, Sacha University Hospital Basel, Basel, Switzerland;
• Patrikidou, Anna University Hospital of Geneva, Geneva, Switzerland;
• Mingrone, Walter B. Kantonsspital Olten, Olten, Switzerland;
• Hermanns, Thomas University Hospital of Zurich, University of Zurich, Zurich, Switzerland;
• Wehrhahn, Tobias Kantonsspital Aarau, Aarau, Switzerland;
• Erdmann, Andreas Kantonsspital Baden, Baden, Switzerland;
• Mueller, Beat Kantonsspital Luzern, Lucerne, Switzerland;
• Bohanes, Pierre Oliver CCAC - Centre de Chimiotherapie Anti-Cancereuse, Lausanne, Switzerland;
• Ribi, Karin IBCSG - International Breast Cancer Study Group, Bern, Switzerland;
• Gillessen, Silke Kantonsspital St. Gallen, St. Gallen, Switzerland;

Cancer Research

Oncology